Business

Title Due Date Maximum Award Amount Sort descending Description
NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) Varies

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists.The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=340748
Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional) Varies

The purpose of this funding opportunity announcement (FOA) is to inspire and support research to advance the drug and device development tools for ultimate submission to DDT or MDDT tool qualification program within either FDAs CDER or CDRH. The funding will be used to further the development of tools that, once qualified, will be available to fill unmet needs in SUD biomedical product development. This FOA ultimately aims to bring innovative treatments to SUD patients faster.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=341058
Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required) Varies

The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343239
NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional) Varies

This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) awardees from underrepresented groups (URGs), while promoting scientific advancements through diversification of NCIs investigator pool. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are eligible to apply.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343329
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional) Varies

This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=343933
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344764
National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional) Varies

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=344891
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) Varies

The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=345102
NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) Varies

This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDAs mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are required. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=345364
Centers for AIDS Research (P30 Clinical Trial Not Allowed) Varies

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=346745